Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials

BACKGROUND: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed to provide benefit in phase-III trials. Success of ICI depends on the presenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Mankor, Joanne M., Disselhorst, Maria J., Poncin, Myrthe, Baas, Paul, Aerts, Joachim G.J.V., Vroman, Heleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658658/
https://www.ncbi.nlm.nih.gov/pubmed/33166791
http://dx.doi.org/10.1016/j.ebiom.2020.103040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658658/
https://www.ncbi.nlm.nih.gov/pubmed/33166791
http://dx.doi.org/10.1016/j.ebiom.2020.103040

Ejemplares similares